Von dem Buch 36th Hemophilia Symposium Hamburg 2005 - Epidemiology; Hemophilia Therapy - Management of Bleedings and Inhibitors; Orthopedic Treatment in Hemophiliacs; Hemostaseologic Diagnosis; Pediatric Hemostaseology; Free Lectures haben wir 2 gleiche oder sehr ähnliche Ausgaben identifiziert!
Falls Sie nur an einem bestimmten Exempar interessiert sind, können Sie aus der folgenden Liste jenes wählen, an dem Sie interessiert sind:
100%: Inge Scharrer, Wolfgang Schramm, G. Auerswald, A. Kurth, J. Oldenburg, W. Schramm, B. Zieger, Herausgeber: Inge Scharrer, Herausgeber: Wolfgang Schramm, Mitarbeiter: G. Auerswald, Mitarbeiter: A. Kurth, Mitarbeiter: J. Oldenburg, Mitarbeiter: W. Schramm, : 36th Hemophilia Symposium Hamburg 2005 - Epidemiology; Hemophilia Therapy - Management of Bleedings and Inhibitors; Orthopedic Treatment in Hemophiliacs; Hemostaseologic Diagnosis; Pediatric Hemostaseology; Free Lectures (ISBN: 9783540367154) in Deutsch, auch als eBook.Nur diese Ausgabe anzeigen…
67%: G. Auerswald/ A. Kurth/ J. Oldenburg/ W. Schramm/ B. Zieger: 36th Hemophilia Symposium Hamburg 2005 (ISBN: 9783540367147) 2007. Ausgabe, in Englisch.Nur diese Ausgabe anzeigen…
36th Hemophilia Symposium Hamburg 2005 - Epidemiology; Hemophilia Therapy - Management of Bleedings and Inhibitors; Orthopedic Treatment in Hemophiliacs; Hemostaseologic Diagnosis; Pediatric Hemostaseology; Free Lectures
14 Angebote vergleichen
| Preise | 2017 | 2018 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Schnitt | € 190,39 | € 196,40 | € 160,49 | € 191,23 | € 117,69 |
| Nachfrage |
1
36th Hemophilia Symposium Hamburg 2005 Epidemiology Hemophilia Therapy Orthopedic Treatment in Hemophiliacs Hemostaseologic Diagnosis Pediatric Hemostaseology Free Lectures (u. a.) (2006)
~EN PB NWISBN: 9783540367147 bzw. 3540367144, vermutlich in Englisch, 319 Seiten, 2007. Ausgabe, Springer Berlin, Taschenbuch, neu.
Lieferung aus: Deutschland, Versandkosten nach: Deutschland, Versandkostenfrei.
Von Händler/Antiquariat, Buchbär, [6122477].
About 31% of the patients with a factor VIII replacement therapy develop a factor VIII inhibitor.From these are 23% low-responder ( 5BE) [8].In the case of severe hemophilia B,about 10.5% of the patients develop inhibitory antibodies [9]. Anti-factor VIII-antibodies are also seen in 15-78% healthy people without hemophilia [7, 17, 19]. Lacroix-Desmazes et al. [10, 11] showed anti-idiotypic antibodies neutralizing the inhibitory activity of the an- factor VIII antibodies in healthy people. Well-known predisposing factors for inhibitor formation are genetic features of factor VIII,which include large deletions,nonsense mutations or intrachromosomal recombinations [5, 23].Also, ethnic groups other than Caucasians (e.g.Africans) have a higher risk of developing inhibitors.Other risk factors are presumably de- ved from the immune system. For instance, a reduction of the inhibitor was seen with lower CD4+ T helper cell counts in HIV positive hemophilic patients [3,4].The development of inhibitors is very likely to be a Th-2 mediated event where cyto- nes and their receptors,T-cell receptors and the Major Histocompatibility Complex may also play an important role. Theoretical Background The substituted factor is an unknown protein for patients with a severe he- philia. Fig. 1. The normal immunoresponse (according to BAENKLER [2]) Abbreviations: TCR - T cell-receptor APC - antigen presenting cell 36 I.Wieland et al. 2006, Taschenbuch, Neuware, 540g, 2007, 319, Sofortüberweisung, PayPal, Banküberweisung.
Von Händler/Antiquariat, Buchbär, [6122477].
About 31% of the patients with a factor VIII replacement therapy develop a factor VIII inhibitor.From these are 23% low-responder ( 5BE) [8].In the case of severe hemophilia B,about 10.5% of the patients develop inhibitory antibodies [9]. Anti-factor VIII-antibodies are also seen in 15-78% healthy people without hemophilia [7, 17, 19]. Lacroix-Desmazes et al. [10, 11] showed anti-idiotypic antibodies neutralizing the inhibitory activity of the an- factor VIII antibodies in healthy people. Well-known predisposing factors for inhibitor formation are genetic features of factor VIII,which include large deletions,nonsense mutations or intrachromosomal recombinations [5, 23].Also, ethnic groups other than Caucasians (e.g.Africans) have a higher risk of developing inhibitors.Other risk factors are presumably de- ved from the immune system. For instance, a reduction of the inhibitor was seen with lower CD4+ T helper cell counts in HIV positive hemophilic patients [3,4].The development of inhibitors is very likely to be a Th-2 mediated event where cyto- nes and their receptors,T-cell receptors and the Major Histocompatibility Complex may also play an important role. Theoretical Background The substituted factor is an unknown protein for patients with a severe he- philia. Fig. 1. The normal immunoresponse (according to BAENKLER [2]) Abbreviations: TCR - T cell-receptor APC - antigen presenting cell 36 I.Wieland et al. 2006, Taschenbuch, Neuware, 540g, 2007, 319, Sofortüberweisung, PayPal, Banküberweisung.
2
36th Hemophilia Symposium Hamburg 2005 Epidemiology Hemophilia Therapy Orthopedic Treatment in Hemophiliacs Hemostaseologic Diagnosis Pediatric Hemostaseology Free Lectures (u. a.) (2006)
~EN PB NWISBN: 9783540367147 bzw. 3540367144, vermutlich in Englisch, 319 Seiten, 2007. Ausgabe, Springer Berlin, Taschenbuch, neu.
Lieferung aus: Deutschland, Versandkosten nach: Deutschland, Versandkostenfrei.
Von Händler/Antiquariat, preigu, [5789586].
About 31% of the patients with a factor VIII replacement therapy develop a factor VIII inhibitor.From these are 23% low-responder ( 5BE) [8].In the case of severe hemophilia B,about 10.5% of the patients develop inhibitory antibodies [9]. Anti-factor VIII-antibodies are also seen in 15-78% healthy people without hemophilia [7, 17, 19]. Lacroix-Desmazes et al. [10, 11] showed anti-idiotypic antibodies neutralizing the inhibitory activity of the an- factor VIII antibodies in healthy people. Well-known predisposing factors for inhibitor formation are genetic features of factor VIII,which include large deletions,nonsense mutations or intrachromosomal recombinations [5, 23].Also, ethnic groups other than Caucasians (e.g.Africans) have a higher risk of developing inhibitors.Other risk factors are presumably de- ved from the immune system. For instance, a reduction of the inhibitor was seen with lower CD4+ T helper cell counts in HIV positive hemophilic patients [3,4].The development of inhibitors is very likely to be a Th-2 mediated event where cyto- nes and their receptors,T-cell receptors and the Major Histocompatibility Complex may also play an important role. Theoretical Background The substituted factor is an unknown protein for patients with a severe he- philia. Fig. 1. The normal immunoresponse (according to BAENKLER [2]) Abbreviations: TCR - T cell-receptor APC - antigen presenting cell 36 I.Wieland et al. 2006, Taschenbuch, Neuware, 540g, 2007, 319, Sofortüberweisung, PayPal, Banküberweisung.
Von Händler/Antiquariat, preigu, [5789586].
About 31% of the patients with a factor VIII replacement therapy develop a factor VIII inhibitor.From these are 23% low-responder ( 5BE) [8].In the case of severe hemophilia B,about 10.5% of the patients develop inhibitory antibodies [9]. Anti-factor VIII-antibodies are also seen in 15-78% healthy people without hemophilia [7, 17, 19]. Lacroix-Desmazes et al. [10, 11] showed anti-idiotypic antibodies neutralizing the inhibitory activity of the an- factor VIII antibodies in healthy people. Well-known predisposing factors for inhibitor formation are genetic features of factor VIII,which include large deletions,nonsense mutations or intrachromosomal recombinations [5, 23].Also, ethnic groups other than Caucasians (e.g.Africans) have a higher risk of developing inhibitors.Other risk factors are presumably de- ved from the immune system. For instance, a reduction of the inhibitor was seen with lower CD4+ T helper cell counts in HIV positive hemophilic patients [3,4].The development of inhibitors is very likely to be a Th-2 mediated event where cyto- nes and their receptors,T-cell receptors and the Major Histocompatibility Complex may also play an important role. Theoretical Background The substituted factor is an unknown protein for patients with a severe he- philia. Fig. 1. The normal immunoresponse (according to BAENKLER [2]) Abbreviations: TCR - T cell-receptor APC - antigen presenting cell 36 I.Wieland et al. 2006, Taschenbuch, Neuware, 540g, 2007, 319, Sofortüberweisung, PayPal, Banküberweisung.
3
36th Hemophilia Symposium Hamburg 2005 (2006)
~EN PB NWISBN: 9783540367147 bzw. 3540367144, vermutlich in Englisch, 319 Seiten, Springer-Verlag GmbH, Taschenbuch, neu.
Lieferung aus: Deutschland, Versandkosten nach: Deutschland, Versandkostenfrei.
Von Händler/Antiquariat, buchversandmimpf2000, [3715720].
Neuware - About 31% of the patients with a factor VIII replacement therapy develop a factor VIII inhibitor.From these are 23% low-responder (, 02.11.2006, Taschenbuch, Neuware, 236x159x15 mm, 518g, 319, PayPal, Banküberweisung.
Von Händler/Antiquariat, buchversandmimpf2000, [3715720].
Neuware - About 31% of the patients with a factor VIII replacement therapy develop a factor VIII inhibitor.From these are 23% low-responder (, 02.11.2006, Taschenbuch, Neuware, 236x159x15 mm, 518g, 319, PayPal, Banküberweisung.
4
36th Hemophilia Symposium Hamburg 2005 - Epidemiology; Hemophilia Therapy - Management of Bleedings and Inhibitors; Orthopedic Treatment in Hemophiliacs; Hemostaseologic Diagnosis; Pediatric Hemostaseology; Free Lectures (2005)
DE NW EB DLISBN: 9783540367154 bzw. 3540367152, in Deutsch, Springer Berlin, neu, E-Book, elektronischer Download.
Lieferung aus: Deutschland, Versandkostenfrei.
36th Hemophilia Symposium Hamburg 2005: About 31% of the patients with a factor VIII replacement therapy develop a factor VIII inhibitor.From these are 23% low-responder ( 5BE) [8].In the case of severe hemophilia B,about 10.5% of the patients develop inhibitory antibodies [9]. Anti-factor VIII-antibodies are also seen in 1578% healthy people without hemophilia [7, 17, 19]. Lacroix-Desmazes et al. [10, 11] showed anti-idiotypic antibodies neutralizing the inhibitory activity of the an- factor VIII antibodies in healthy people. Well-known predisposing factors for inhibitor formation are genetic features of factor VIII,which include large deletions,nonsense mutations or intrachromosomal recombinations [5, 23].Also, ethnic groups other than Caucasians (e.g.Africans) have a higher risk of developing inhibitors.Other risk factors are presumably de- ved from the immune system. For instance, a reduction of the inhibitor was seen with lower CD4+ T helper cell counts in HIV positive hemophilic patients [3,4].The development of inhibitors is very likely to be a Th-2 mediated event where cyto- nes and their receptors,T-cell receptors and the Major Histocompatibility Complex may also play an important role. Theoretical Background The substituted factor is an unknown protein for patients with a severe he- philia. Fig. 1. The normal immunoresponse (according to BAENKLER [2]) Abbreviations: TCR T cell-receptor APC antigen presenting cell 36 I.Wieland et al. Englisch, Ebook.
36th Hemophilia Symposium Hamburg 2005: About 31% of the patients with a factor VIII replacement therapy develop a factor VIII inhibitor.From these are 23% low-responder ( 5BE) [8].In the case of severe hemophilia B,about 10.5% of the patients develop inhibitory antibodies [9]. Anti-factor VIII-antibodies are also seen in 1578% healthy people without hemophilia [7, 17, 19]. Lacroix-Desmazes et al. [10, 11] showed anti-idiotypic antibodies neutralizing the inhibitory activity of the an- factor VIII antibodies in healthy people. Well-known predisposing factors for inhibitor formation are genetic features of factor VIII,which include large deletions,nonsense mutations or intrachromosomal recombinations [5, 23].Also, ethnic groups other than Caucasians (e.g.Africans) have a higher risk of developing inhibitors.Other risk factors are presumably de- ved from the immune system. For instance, a reduction of the inhibitor was seen with lower CD4+ T helper cell counts in HIV positive hemophilic patients [3,4].The development of inhibitors is very likely to be a Th-2 mediated event where cyto- nes and their receptors,T-cell receptors and the Major Histocompatibility Complex may also play an important role. Theoretical Background The substituted factor is an unknown protein for patients with a severe he- philia. Fig. 1. The normal immunoresponse (according to BAENKLER [2]) Abbreviations: TCR T cell-receptor APC antigen presenting cell 36 I.Wieland et al. Englisch, Ebook.
5
36th Hemophilia Symposium Hamburg 2005 (2007)
DE NW EBISBN: 9783540367154 bzw. 3540367152, in Deutsch, Springer, neu, E-Book.
Lieferung aus: Deutschland, Sofort per Download lieferbar.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
6
36th Hemophilia Symposium Hamburg 2005 (2005)
DE NWISBN: 9783540367154 bzw. 3540367152, in Deutsch, Springer, Berlin/Heidelberg, Deutschland, neu.
Lieferung aus: Vereinigtes Königreich Großbritannien und Nordirland, Versandkostenfrei.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
7
36th Hemophilia Symposium Hamburg 2005
DE NWISBN: 9783540367154 bzw. 3540367152, in Deutsch, Springer, Berlin/Heidelberg, Deutschland, neu.
Lieferung aus: Deutschland, Sofort per Download lieferbar.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
9
Symbolbild
Inge Scharrer (Editor), Wolfgang Schramm (Editor), G. Auerswald (Contributor), A. Kurth (Contributor), J. Oldenburg (Contributor), W. Schramm (Contributor), B. Zieger (Contributor)
36th Hemophilia Symposium Hamburg 2005: Epidemiology; Hemophilia Therapy - Management of Bleedings and Inhibitors; Orthopedic Treatment in . Pediatric Hemostaseology; Free Lectures (2006)
~EN PBISBN: 9783540367147 bzw. 3540367144, vermutlich in Englisch, Springer, Taschenbuch.
Lieferung aus: Vereinigte Staaten von Amerika, Versandkosten nach: DEU.
Von Händler/Antiquariat, Ergodebooks.
Springer, 2006-12-20. 2007. Paperback. Used:Good.
Von Händler/Antiquariat, Ergodebooks.
Springer, 2006-12-20. 2007. Paperback. Used:Good.
10
Symbolbild
Editor-Inge Scharrer; Editor-Wolfgang Schramm; Contributor-G. Auerswald; Contributor-A. Kurth; Contributor-J. Oldenburg; Contributor-W. Schramm; Contributor-B. Zieger
36th Hemophilia Symposium Hamburg 2005: Epidemiology; Hemophilia Therapy - Management of Bleedings and Inhibitors; Orthopedic Treatment in . Pediatric Hemostaseology; Free Lectures (2006)
~EN PBISBN: 9783540367147 bzw. 3540367144, vermutlich in Englisch, Springer, Taschenbuch.
Lieferung aus: Vereinigte Staaten von Amerika, Versandkosten nach: DEU.
Von Händler/Antiquariat, Ergodebooks.
Springer, 2006-12-20. Paperback. Used:Good.
Von Händler/Antiquariat, Ergodebooks.
Springer, 2006-12-20. Paperback. Used:Good.
Lade…